Randomized Open-label Multicenter Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Or Metastatic Tyrosine Kinase Inhibitor (tki)-naïve Ros1-positive Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC
    2. Patient has a ROS1 gene rearrangement/fusion as detected by a local test
    3. Patients must not be exposed previously to TKIs that demonstrated activities in ROS1-positive NSCLC (eg, crizotinib, ceritinib, lorlatinib, brigatinib, entrectinib, ensartinib, DS6051b, NVL-520, taletrectinib, foretinib, and cabozantinib)

You may not be eligible for this study if the following are true:

    1. Symptomatic brain metastases or symptomatic leptomeningeal involvement
    2. History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected
    3. Known tumor targetable co-mutations or rearrangements (ie, epidermal growth factorreceptor [EGFR] or ALK)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.